Health Care [ 4/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of medicines and technologies.
The company provides Vants, a model to develop and commercialize its medicines and technologies focuses on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Its clinical product candidate includes IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, sjögren's disease, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.
The company also provides mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease.
In addition, the company offers delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform.
Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 25 | -0.22 Decreased by -14.89% | -0.16 Decreased by -33.68% |
| Feb 11, 25 | -0.20 Increased by +33.73% | -0.24 Increased by +17.17% |
| Nov 12, 24 | -0.31 Increased by +21.75% | -0.26 Decreased by -20.38% |
| Aug 8, 24 | 0.12 Increased by +131.58% | -0.26 Increased by +146.15% |
| May 30, 24 | -0.19 Increased by +5.00% | -0.30 Increased by +36.67% |
| Feb 13, 24 | -0.30 Increased by +38.78% | -0.32 Increased by +6.25% |
| Nov 13, 23 | -0.40 Increased by +4.76% | -0.31 Decreased by -29.03% |
| Aug 14, 23 | -0.38 Increased by +20.83% | -0.30 Decreased by -26.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 9.02 M Decreased by -75.72% | 169.38 M Decreased by -96.68% | Increased by +1.88 K% Decreased by -86.31% |
| Sep 30, 24 | 4.47 M Decreased by -87.94% | -230.18 M Increased by +24.36% | Decreased by -5.14 K% Decreased by -527.09% |
| Jun 30, 24 | 55.13 M Increased by +154.96% | 95.30 M Increased by +132.66% | Increased by +172.85% Increased by +112.81% |
| Mar 31, 24 | 28.93 M Increased by +5.68% | -151.12 M Decreased by -349.52% | Decreased by -522.35% Decreased by -325.37% |
| Dec 31, 23 | 37.14 M Increased by +117.80% | 5.10 B Increased by +1.55 K% | Increased by +13.72 K% Increased by +764.69% |
| Sep 30, 23 | 37.10 M Increased by +196.03% | -304.33 M Increased by +3.67% | Decreased by -820.27% Increased by +67.46% |
| Jun 30, 23 | 21.62 M Increased by +400.67% | -291.82 M Increased by +17.52% | Decreased by -1.35 K% Increased by +83.53% |
| Mar 31, 23 | 27.38 M Increased by +196.82% | -33.62 M Increased by +88.46% | Decreased by -122.80% Increased by +96.11% |